Study guide

8.1 Subcutaneous Infusion Access

CRNI® Exam Study Guide Certified Registered Nurse Infusion

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application & Testing Windows 1.3 Scoring, Results & Recertification

2 Anatomy & Physiology for Infusion Practice

2.1 Vascular Anatomy & Physiology for Infusion 2.2 Body Positioning for Catheter Insertion & Removal 2.3 Vein Selection & Patient Assessment

3 Infection Prevention & Control

3.1 Infection Prevention Strategies & Standard Precautions 3.2 Chain of Infection in Infusion Practice 3.3 Bloodstream Infections & CLABSI Prevention 3.4 Phlebitis: Prevention, Grading & Management

4 Phlebotomy in Infusion Practice

4.1 Blood Sampling & Blood Culture Collection 4.2 Therapeutic Phlebotomy

5 Infusion Equipment & Technology

5.1 Solution Containers, Administration Sets & Filters 5.2 Add-on Devices, Administration Devices & Closed Systems 5.3 Vein Location Devices, Navigation Tools & Securement

6 Peripheral Venous Access Devices

6.1 Short & Long Peripheral Intravenous Catheters 6.2 Midline Catheters 6.3 Peripheral Device Selection Criteria

7 Central Venous Access Devices

7.1 Peripherally Inserted Central Catheters (PICC) 7.2 Non-tunneled Central Venous Catheters 7.3 Tunneled Central Venous Catheters 7.4 Implanted Ports

8 Alternate Access Routes & Device Maintenance

8.1 Subcutaneous Infusion Access 8.2 Intraosseous Access 8.3 Device Maintenance & Care Protocols

9 Special Populations in Infusion Therapy

9.1 Older Adults & Chronic Renal Conditions 9.2 Pediatrics, Immunocompromised, Oncology & Bariatrics

10 Device-Related Complications

10.1 Infiltration & Extravasation 10.2 Catheter Occlusion 10.3 Thrombosis, Air Embolism & Device-Related Systemic Events

11 Fluid & Electrolyte Balance

11.1 Body Composition & Fluid Balance 11.2 Fluid Volume Excess & Deficit 11.3 Electrolyte Disorders 11.4 Maintenance & Replacement Fluids

12 Parenteral Nutrition

12.1 Parenteral Nutrition: Solution Composition 12.2 PN Infectious, Metabolic & Mechanical Complications

13 Anti-infectives, Blood Products & Biologics

13.1 Anti-infective Infusion Therapy 13.2 Blood Products & Transfusion Therapy 13.3 Biologics & Immunologic Therapies

14 Antineoplastic, Cardiovascular & Pain Infusions

14.1 Antineoplastic Infusion Therapy 14.2 Cardiovascular Infusions 14.3 Pain Management Infusions

15 Therapy-Related Complications & Hazardous Drugs

15.1 Rate-Related Complications 15.2 Adverse Drug Reactions 15.3 Hazardous Drug Exposure & Waste Disposal

16 Professional Practice, Documentation & Quality

16.1 Assessment, Consent & Collaborative Care Planning 16.2 Documentation, Laws & Regulatory Agencies 16.3 Evidence-Based Practice & Performance Improvement

8.1 Subcutaneous Infusion Access

Key Takeaways Explain This Topic AI

Subcutaneous (SQ) infusion—including hypodermoclysis for hydration—delivers fluids or selected medications into subcutaneous tissue when IV access is unnecessary, impractical, or not preferred.

Preferred adult sites include abdomen, anterior thigh, and upper arm (or other soft, well-perfused areas away from infection, scar, bone, and planned procedures); rotate sites to reduce local reactions.

Volumes and rates must match tissue absorption capacity and ordered therapy; continuous or intermittent SQ hydration uses conservative rates with frequent site assessment for swelling, leakage, and pain.

Recombinant human hyaluronidase may be used per order/product labeling to temporarily increase interstitial permeability and facilitate SQ fluid absorption for selected hydration protocols.

SQ access is not a substitute for emergency intravascular resuscitation or for therapies that require intravenous pharmacokinetics; match route to drug and clinical goal.

Last updated: August 2026

Subcutaneous access on the CRNI blueprint

Domain 2A.2.c expects infusion nurses to know subcutaneous (SQ) infusion access —including hypodermoclysis (SQ fluid administration for hydration)—as a legitimate alternate route alongside peripheral and central venous devices and intraosseous access. SQ therapy is not “second-class IV.” It is a distinct route with different pharmacokinetics, absorption limits, and complication patterns.

Quick Answer: Subcutaneous infusion delivers fluid or medication into the subcutaneous tissue via a small-gauge needle or soft catheter secured under a dressing. Hypodermoclysis refers specifically to SQ hydration . Common adult sites are the abdomen, anterior thigh, and upper arm . Use site rotation , monitor for local reactions , control volume/rate to tissue tolerance, and consider hyaluronidase when ordered to enhance absorption. SQ is for appropriate non-emergent hydration and selected SQ-labeled drugs —not for replacing failed emergency IV when intravascular delivery is required (then escalate to IO/IV/CVAD as indicated).

Why SQ infusion exists

SQ access supports goals that pure venous access may not optimize:

  • Clinical goal Why SQ may fit
  • Hydration in mild–moderate deficit Avoids repeated failed PIV sticks in frail or dehydrated patients
  • Palliative / hospice comfort care Lower procedural burden; home-friendly hydration or symptom meds

Selected biologics / SQ immunoglobulins / SQ pain meds Labeled for SQ route; patient preference or home self-admin pathways

  • Limited venous capital Preserves veins for future essential IV therapy
  • Intermittent or continuous low-complexity infusions When drug properties and orders support SQ delivery

Exam framing: Choose SQ when the therapy is SQ-appropriate , absorption is acceptable for the clinical goal, and the patient/setting can support site care. Do not choose SQ as a workaround for rapid intravascular volume resuscitation , vasopressors needing IV delivery , or drugs that must be given IV only .

Hypodermoclysis (SQ hydration)

Hypodermoclysis is administration of isotonic (or other ordered) fluids into subcutaneous tissue for rehydration or maintenance fluid support. It is widely used in older adults, palliative care, and settings where venous access is difficult or disproportionate to the hydration need.

Fluids and therapy principles

Prefer fluids and rates ordered and compatible with SQ absorption (commonly isotonic crystalloids for hydration protocols—follow formulary/policy and product guidance).

Absorption depends on interstitial space , local perfusion , volume , and whether hyaluronidase is used.

SQ hydration is not equivalent to large-volume IV boluses for shock. If the patient is unstable and needs immediate intravascular volume and drug delivery, pursue IV or IO access.

Volumes and rates (principles, not fixed recipes)

Exact mL/hour limits vary by protocol, age, site, number of sites, and whether hyaluronidase is used. For exam thinking, master principles :

Tissue has finite absorption capacity —pushing high rates causes pooling, leakage, pain, and poor systemic delivery .

Start within ordered/protocol ranges and reassess the site frequently early in therapy.

Bilateral or multi-site administration may be used in some protocols to distribute volume—never invent multi-site setups without order/policy support.

Titrate or pause if swelling becomes tense, skin blanches excessively, leakage appears, or the patient reports significant pain.

Daily (or more frequent) clinical reassessment of hydration status (mucosa, urine output trends, mental status, labs as ordered) matters as much as pump numbers.

High-yield: The exam may describe progressive arm/abdomen swelling with leakage and ask for the priority action— stop or slow the infusion, assess the site, notify as indicated, and rotate/relocate per protocol —not “increase rate to push fluid in.”

Site selection

Choose soft, accessible subcutaneous tissue with adequate fat pad and intact skin.

Preferred adult regions Rationale Avoid / caution

Abdomen (away from umbilicus, waistband, scars, stomas) Large surface; easy inspection; common for continuous SQ Recent surgery, infection, radiation, ascites with fragile skin

Anterior thigh Good for ambulatory patients; easy self-care teaching Immobility-related edema, skin breakdown, planned procedures

Upper arm (lateral/posterior soft tissue) Convenient for some ambulatory setups Deltoid IM confusion; thin subcutis; clothing friction

Other soft areas per policy (e.g., subclavicular soft tissue in some protocols) Backup when primary sites exhausted Bony prominences, breast tissue (context), near joints with high motion

Absolute/relative site exclusions (concept list): active infection, inflammation, bruising/hematoma, broken skin, severe edema or poor perfusion of the area, scarred/irradiated tissue, sites over implants when contraindicated, and areas that will be compressed by tight garments or restraints.

Insertion and securement principles

Hand hygiene , explain procedure, position for comfort and site access.

Skin antisepsis with approved agent; allow full dry time.

Insert a small-gauge metal needle or soft SQ set at the angle appropriate to device IFU (often 30–45° or per product; some soft sets are designed for flatter insertion).

Aspirate per product/policy if indicated (blood return suggests unintended intravascular placement—do not infuse as SQ).

Secure with transparent or product-specific dressing so the site remains visible when possible.

Label date/time/site as required; connect ordered fluid/medication with compatible set.

Educate patient/caregiver: report pain, redness, leakage, fever, or dressing failure.

Site rotation and local reactions

Site rotation reduces cumulative tissue trauma, fibrosis, and local adverse reactions—especially for chronic SQ therapies (e.g., some biologics, SQ immunoglobulin, continuous SQ meds).

Local reaction Clues Nursing response principles

Edema / pooling Soft swelling, dependent fluid, leakage at insertion Reduce rate/volume; reassess absorption; rotate site; check tubing for free flow issues

Erythema / irritation Redness, warmth, tenderness Differentiate mild expected reaction vs infection; stop if progressive or systemic signs

Pain / burning Patient report during infusion Pause; verify rate, drug concentration, and site integrity; do not force through severe pain

Hematoma / bleeding Bruising, expanding ecchymosis Hold pressure as needed; avoid re-stick same area; review anticoagulants

Infection (cellulitis) Expanding erythema, purulence, fever Remove access; culture/treat per provider; document; new site only when appropriate

Lipohypertrophy / fibrosis (chronic use) Firm rubbery tissue, poor absorption Rotate rigorously; avoid injecting into hypertrophied tissue

Exam trap: Treating every red SQ site as harmless “expected irritation” when systemic signs or spreading cellulitis are present.

Hyaluronidase

Recombinant human hyaluronidase temporarily depolymerizes hyaluronic acid in the extracellular matrix, increasing interstitial permeability and facilitating dispersion/absorption of SQ fluid. It appears on exams as an adjunct for selected SQ hydration protocols and certain SQ drug co-formulations.

Key points for CRNI:

Use only when ordered and consistent with product labeling and organizational policy.

Know it is an absorption facilitator , not a treatment for shock by itself.

Monitor for local and hypersensitivity reactions (rare but tested conceptually).

Even with hyaluronidase, site assessment remains mandatory—enhanced absorption does not eliminate overload or infection risk.

Selected SQ medications (route discipline)

Beyond hydration, SQ infusion or injection pathways may include:

  • Continuous SQ opioid or other palliative symptom infusions (when ordered and compatible)
  • SQ biologics / monoclonal antibodies formulated for SQ use
  • SQ immunoglobulin replacement in immunodeficiency pathways
  • Other drugs explicitly labeled for SQ administration

Never assume an IV medication can be “run SQ because the PIV fell out.” Pharmacokinetics, concentration, pH, and volume matter. Wrong-route errors are high-harm events.

Comparison: SQ vs peripheral IV vs IO (selection snapshot)

  • Feature SQ / hypodermoclysis Peripheral IV Intraosseous
  • Primary role Hydration & SQ-labeled meds Routine intravascular therapy Emergency access when IV fails
  • Onset Delayed vs IV (absorption-dependent) Immediate intravascular Rapid to central circulation via marrow
  • Shock resuscitation Not primary Preferred if obtainable Bridge when IV not achievable

Dwell concept Hours to days per set/site policy; rotate Clinically indicated Short —remove ASAP when IV/CVAD established (often within ~24 h)

Scenario

An 84-year-old hospice patient has mild dehydration, refuses further PIV attempts, and is hemodynamically stable. The provider orders SQ isotonic fluid via hypodermoclysis with site assessment q2h initially. Best thinking: select abdomen or thigh with intact skin, insert/secure SQ set aseptically, start within ordered rate, monitor for pooling/leakage, rotate if local intolerance develops, and reassess clinical hydration—not force IV sticks for comfort-focused mild dehydration.

  • High-yield exam traps
  • Using SQ hydration as primary therapy for hypovolemic or septic shock
  • Ignoring site rotation for chronic SQ therapy
  • Infusing IV-only drugs SQ without labeling/order support
  • Failing to stop/slow for tense swelling, leakage, or progressive cellulitis
  • Confusing hyaluronidase with a vasopressor or volume expander substitute
  • Selecting infected, scarred, or irradiated sites for “convenience”